The BaseLaunch Healthcare Accelerator program from BaselArea.swiss started on September 14. Over 100 applications were received from more than 30 countries, and the selection committee has selected 13 projects to go on to Phase I. Now, the project teams will work with industry experts to further develop their business case over the next three months.
More than 100 projects from over 30 countries were submitted to the BaseLaunch accelerator program from BaselArea.swiss. The submitted projects ranged from therapeutics and diagnostics to digital healthcare and medtech. Instead of 10 as originally planned, the selection committee chose 13 promising projects, which will now proceed to Phase I. "The innovation potential of the project proposals was impressive," says BaseLaunch Selection Committee Chairwoman Trudi Haemmerli, CEO of PerioC Ltd and Managing Director of TruStep Consulting GmbH. “We look forward to seeing how the chosen project teams fine-tune their business cases during Phase I.”
According to Stephan Emmerth, the BaselArea.swiss Business Development Manager for BaseLaunch, the selected projects cover a wide range of objectives: from new approaches for the treatment of diseases such as Alzheimer's or novel immunotherapies to innovative drug delivery methods and next-generation gene therapies for cancer treatment. Other projects focus on new diagnostic procedures for finding cancer biomarkers or revolutionizing the detection of neurological diseases by deploying digital measurement methods.
The development stages of the projects were just as varied. Some projects were submitted by entrepreneurs wishing to establish a company with the support of BaseLaunch. Other projects came from existing startups that had already successfully managed the initial rounds of financing and wanted to further develop the company with the help of BaseLaunch. The founders of these companies and members of project teams also had different professional career histories. Some of the applicants selected for Phase I have many years of R&D experience in the industry; others come from a university background.
"We have chosen the most promising projects. Additionally, selected projects should benefit as much as possible from BaseLaunch and its regional life sciences ecosystem," says Alethia de León, Managing Director of BaseLaunch. “We paid particular attention to a sound scientific and technical foundation, a high level of innovation and the entrepreneurial potential of the founding team.” Alethia also commented on the productive and collaborative selection process with representatives from healthcare partners that included Johnson & Johnson Innovation, Novartis Venture Fund, Pfizer and Roche. "Our discussions during the selection process were very constructive," she says.
The 13 selected startups will have three months from September 14 to develop their business ideas. They will be supported by the BaseLaunch team as well as a number of experienced entrepreneurs and consultants. In this first phase, up to CHF 10,000 will be available for each of the projects. The selection committee will then select three of the Phase I projects to progress to Phase II. This phase lasts for 12 months, with each project receiving funding of up to CHF 250,000. The selected project teams in Phase II will also have access to the BaseLaunch Lab in the Switzerland Innovation Park Basel Area, where they will be expected to achieve important research milestones and further develop their business cases.
Overview of the selected projects:
ABBA Therapeutics develops therapeutic antibodies against novel targets for cancer immunotherapy.
The β-catenin project aims to develop novel therapeutics for the treatment of colorectal, lung, liver, breast, brain and ovarian cancers by removing pathological proteins from the human body.
CellSpring analyzes human cells grown in special 3-Dimensional environments to develop new tools for diagnosing early-stage cancer.
Eyemove strives to detect early-stage neurological diseases through eye-tracking.
Polyneuron Pharmaceuticals is committed to the development of a promising new drug class to treat autoimmune disorders.
The SERI project develops new medicines to treat anxiety and stress related disorders by modulating the activity of cannabinoid molecules in the human body.
SunRegen develops novel drugs for neurodegenerative diseases.
T3 Pharma develops the next generation bacterial cancer therapy.
The mission of T-CURX is to exploit its unique ‘UltraModularCAR’ platform to provide best-in-class immunotherapy.
The mission of TEPTHERA is to offer individualized therapeutic cancer vaccines.
TheraNASH develops precision medicine for fatty liver disease (NASH) - a rising cause of liver cancer world-wide.
VERSAMEB is a regenerative medicine research and development company.
One biotech in stealth mode is developing novel Immuno-Oncology drugs.